Cullinan Therapeutics
Develops bispecific T-cell engagers for autoimmune disease and cancer through a hub-and-spoke drug-development model.
Something off on this page? Send us feedback.
Breakdown13F · Form 4
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 61.46M · Float 44.16M · 71.9% free float
A Form 4 total here can count shares the filer formally disclaims — an award voted by proxy, for instance — which the holder's own Schedule 13D/G excludes, so where the two disagree the schedule's smaller figure is used.
Institutions13F, as of Jun 30, 2026
193 holders · 72.81M shares · 35 new positions · 119 increased · 46 reduced · 21 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Bioimpact Capital LLC | 9.73M | 15.83% | +2.08M | Aug 14, 2026 |
| LYNX1 Capital Management LP | 8.96M | 14.58% | 0 | Aug 13, 2026 |
| BVF Inc/IL | 5.75M | 9.36% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 5.23M | 8.51% | +782.8K | Aug 7, 2026 |
| Price T Rowe Associates Inc /MD/ | 3.83M | 6.23% | +1.80M | Aug 14, 2026 |
| State Street Corp | 3.67M | 5.97% | +1.12M | Aug 7, 2026 |
| Kynam Capital Management, LP | 3.11M | 5.07% | 0 | Aug 14, 2026 |
| Vanguard Capital Management LLC | 2.61M | 4.25% | +131.0K | Aug 13, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| LYNX1 Capital Management LP | 9.80% | 5.77M | 13G | Nov 14, 2025 ↗ |
| BlackRock, Inc. | 7.50% | 4.34M | Nov 8, 2024 ↗ | |
| T. Rowe Price Associates, Inc. | 6.20% | 3.83M | 13G | Aug 14, 2026 ↗ |
| Biotechnology Value Fund L P | 5.80% | 3.55M | 13G | May 15, 2026 ↗ |
| Kynam Capital Management, LP | 5.27% | 3.11M | 13G | Mar 4, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Lynx1 Capital Management LP | 10 percent owner | 5.77M | 9.38% | Oct 30, 2025 |
| Nadim Ahmed | director, officer: President and CEO | 390.8K | 0.64% | Feb 25, 2026 |
| Jennifer Michaelson | officer: Chief Scientific Officer | 162.8K | 0.26% | Aug 14, 2026 |
| Jeffrey Alan Jones | officer: Chief Medical Officer | 160.0K | 0.26% | Feb 25, 2026 |
| Jacquelyn L. Sumer | officer: Chief Legal Officer | 130.6K | 0.21% | Jul 2, 2026 |
| Mary Kay Fenton | officer: Chief Financial Officer | 127.9K | 0.21% | Jul 2, 2026 |
5 ten-percent owners hold 22.86M shares by Form 4 — the 13D/G table above shows those stakes, the figure above counts officers and directors only · 12 people have not refiled in the last 18 months (6.70M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 13, 2026 | Jennifer Michaelsonofficer: Chief Scientific Officer | Sale | 30,000 | $20.26 | 162,844 |
| Jul 6, 2026 | Jennifer Michaelsonofficer: Chief Scientific Officer | Sale | 8,000 | $17.82 | 162,844 |
| May 5, 2026 | Jennifer Michaelsonofficer: Chief Scientific Officer | Sale · 2 lots | 8,000 | $14.62 | 166,844 |
| Mar 5, 2026 | Jennifer Michaelsonofficer: Chief Scientific Officer | Sale | 8,000 | $15.68 | 170,844 |
| Feb 25, 2026 | Jennifer Michaelsonofficer: Chief Scientific Officer | Sale | 1,780 | $14.14 | 174,844 |
| Feb 24, 2026 | Jacquelyn L. Sumerofficer: Chief Legal Officer | Sale | 3,601 | $14.47 | 128,089 |
| Feb 24, 2026 | Jeffrey Alan Jonesofficer: Chief Medical Officer | Sale | 4,582 | $14.47 | 159,968 |
| Feb 24, 2026 | Nadim Ahmeddirector, officer: President and CEO | Sale | 13,515 | $14.47 | 390,803 |
| Feb 24, 2026 | Jennifer Michaelsonofficer: Chief Scientific Officer | Sale | 3,601 | $14.47 | 176,624 |
| Feb 23, 2026 | Jennifer Michaelsonofficer: Chief Scientific Officer | Sale | 1,752 | $13.99 | 180,225 |
CongressHouse and Senate disclosures
Not reported.